Horizon scanning for novel therapeutics for the treatment of prostate cancer

Expert Opinion on Investigational Drugs

Volumn 19, Issue 12, 2010, Pages 1487-1502

  Bianchini, Diletta ^a   Zivi, Andrea ^a   Sandhu, Shahneen ^a   De Bono, Johann S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

drug development; metastatic castration resistant prostate cancer; molecular target; targeted therapy

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ABIRATERONE; ADENOSINE TRIPHOSPHATE DEPENDENT PROTEINASE; ANDROGEN RECEPTOR; ANDROSTANOLONE; BCR ABL PROTEIN; CHAPERONE; CORTICOTROPIN; CP 751871; CYTOCHROME P450 17; DASATINIB; DOCETAXEL; GONADORELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE INHIBITOR; KETOCONAZOLE; METRONIDAZOLE; MINERALOCORTICOID; MONOCLONAL ANTIBODY IMC 1C11; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; OBLIMERSEN; OGX 011; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PREDNISONE; PROSTVAC; PROVENGE; STEROID 17ALPHA MONOOXYGENASE; TEMSIROLIMUS; TESTOSTERONE; TRANSCRIPTION FACTOR ER81; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AVIAN ERYTHROBLASTOSIS ONCOVIRUS; BINDING AFFINITY; BONE TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROS; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DRUG TARGETING; FATIGUE; FEVER; FLUID RETENTION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOKALEMIA; IMMUNE RESPONSE; LIGAND BINDING; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RASH; REVIEW; RIGOR; SIGNAL TRANSDUCTION; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; TUMOR CELL;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; HUMANS; MALE; PROSTATIC NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 78649518943     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.514261     Document Type: Review

References (158)

1. American Cancer Society, Cancer Facts and Figures; 2009. Available from: http://www.cancer.org/ Research/CancerFactsFigures/index
2. Keller ET, Zhang J, Cooper CR, et al. Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev 2001;20:333-49
3. Cooperberg MR, Broering JM, Litwin MS. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry [review]. J Urol 2004;171(4):1393-401
4. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941;1:293-7
5. Eisenberger M.A., Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339(15):1036-42
6. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351(15):1502-12
7. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351(15):1513-20
8. Sternberg CN, Petrylak DP, Sartor O, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. J Clin Oncol 2009;27(32):5431-8
9. Lee JJ, Kelly WK. Epothilones: tubulin polymerization as a novel target for prostate cancer therapy. Nat Clin Pract Oncol 2009;6(2):85-92
10. Mita AC, Denis LJ, Rowinsky EK. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009;15(2):723-30
11. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26(7):1148-59
12. Mohler JL, Gregory CW, Ford III OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10(2):440-8
13. Mitsiades N, Schultz BS, Taylor H, et al. Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: targets for novel personalized therapies. J Clin Oncol 2009;27(15S):abstract 5002
14. Titus M.A., Schell MJ, Lih FB, et al. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7
15. Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment targets. Eur Urol 2009;56(4):594-605
16. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer [review]. Nat Rev Cancer 2001;1(1):34-45
17. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26(28):4563-71
18. De Coster R, Caers I, Coene MC, et al. Effects of high dose ketoconazole therapy on the main plasma testicular and adrenal steroids in previously untreated prostatic cancer patients. Clin Endocrinol (Oxf) 1986;24:657-64
19. Figg WD, Liu Y, Arlen P, et al. A randomized, phase II trial of ketoconazole plus alendronate versus ketoconazole alone in patients with androgen independent prostate cancer and bone metastases. J Urol 2005;173(3):790-6
20. O'Donnell A, Judson I, Dowsett M. Hormonal impact of the 17alpha-hydroxylase/C (17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317-25
21. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27(23):3742-8
22. Reid AH, Attard G, Danila DC, et al. Significant and sustained anti-tumor activity in post-docetaxel castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28(9):1489-95
23. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol 2010:1481-8
24. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28(9):1496-501
25. Howard CS, Steven PB. Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer. Cancer Cell 2009;15(6):461-3
26. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10(1):33-9
27. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol 2009;10(10):981-91
28. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010;375(9724):1437-46
29. Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009;20(1):27-33
30. Attard G, Clark J, Ambroisine L, et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 2008;99(2):314-20
31. Dreicer R, Agus DB, MacVicar GR, et al. Safety, pharmacokinetics, and efficacy of TAK-700 in metastatic castration-resistant prostrate cancer: a phase I/II, open-label study. J Clin Oncol 2010;28(7S):abstract 3084
32. Banerji U. Heat shock protein 90 as a drug target: some like it hot [review]. Clin Cancer Res 2009;15(1):9-14
33. Powers MV, Workman P. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors. Endocr Relat Cancer 2006;13(Suppl 1):S125-35
34. Saporita AJ, Ai J, Wang Z, et al. The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate 2007;67(5):509-20
35. Solit DB, Egorin M, Valentin G, et al. Phase I pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17- demethoxygeldanamycin). J Clin Oncol 2004;22(14S):3032
36. Heath EI, Hillman DW, Vaishampayan U, et al. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 2008;14(23):7940-6
37. Pacey SC. A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours - ASCO. J Clin Oncol 2009;27(15S):abstract 3534
38. Gibbons NB, Watson RW, Coffey RN, et al. Heat-shock proteins inhibit induction of prostate cancer cell apoptosis. Prostate 2000;45(1):58-65
39. Rizzi F, Caccamo AE, Belloni L, et al. Clusterin is a short half-life, poly-ubiquitinated protein, which controls the fate of prostate cancer cells. J Cell Physiol 2009;219(2):314-23
40. Steinberg J, Oyasu R, Lang S. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer. Clin Cancer Res 1997;3:1707-11
41. Redondo M, Villar E, Torres-Munoz J, et al. Overexpression of clusterin in human breast carcinoma. Am J Pathol 2000;157:393-9
42. Rauhala HE, Porkka KP, Saramaki OR, et al. Clusterin is epigenetically regulated in prostate cancer. Int J Cancer 2008;23:1601-9
43. Zhang H, Kim JK, Edwards CA. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol 2005;7:909-15
44. Humphreys DT, Carver JA, Easterbrook-Smith SB, et al. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J Biol Chem 1999;274(11):6875-81
45. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2000;6:1655-63
46. Chi KN, Hotte SJ, Yu E, et al. Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/ prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2009;27(15S):abstract 5012
47. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
48. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84
49. Welsbie DS, Xu J, Chen Y, et al. Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 2009;69(3):958-66
50. Bjorkman M, Iljin K, Halonen P, et al. Defining the molecular action of HDAC inhibitors and synergism with androgen deprivation in ERG-positive prostate cancer. Int J Cancer 2008;123:2774-81
51. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269(1):7-17
52. Bradley D, Rathkopf D, Dunn R, et al. Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 2009;115(23):5541-9
53. Molife LR, Attard G, Fong PC, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol 2010;21(1):109-13
54. Attard G, Ang JE, Olmos D, et al. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. J Clin Pathol 2008;61(8):891-6
55. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-400
56. Attard G, Reid AH, Olmos D, et al. Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven. Cancer Res 2009;69(12):4937-40
57. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer [review]. Nat Rev Cancer 2008;8(7):497-511
58. Danila DC, Anand A, Sung C, et al. Molecular profiling of circulating tumor cells (CTC) in patients with castrate metastatic prostate cancer (CMPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy (abstract 31). Genitourinary Cancer Symposium; 5-7 March 2010, San Francisco, USA
59. Pollak M, Perdue JF, Margolese RG, et al. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987;38(1-2):223-30
60. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin 2009;59(2):111-37
61. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28:3009-21
62. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumour growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005;11(5):2063-73
63. Olmos D, Okuno S, Schuetze SM, et al. Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma. J Clin Oncol 2008;26:abstract 10501
64. Karp DD, Novello S, Cardenal F, et al. Continued high activity of figitumumab (CP-751,871) combination therapy in squamous lung cancer. J Clin Oncol 2009;27(15S):abstract 8072
65. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007;13(19):5834-40
66. De Bono JS, Attard G, Adjei A, et al. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 2007;13(12):3611-16
67. Higano C, Alumkal J, Ryan CJ, et al. A phase II study evaluating the efficacy and safety of single agent IMC A12, a monoclonal antibody (MAb), against the insulin-like growth factor-1 receptor (IGF-IR), as monotherapy in patients with metastastic, asymptomatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2009;27(15S):abstract 5142
68. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009;15(15):4799-805
69. Gray IC, Stewart LM, Phillips SM, et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br J Cancer 1998;78(10):1296-300
70. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 1998;273(22):13375-8
71. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer [review]. Cancer Cell 2007;12(1):9-22
72. Knudson Jr AG. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971;68(4):820-3
73. Di Cristofano A, Kotsi P, Peng YF, et al. Impaired Fas response and autoimmunity in Pten+/- mice. Science 1999;285(5436):2122-5
74. Chen Z, Trotman LC, Shaffer D. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436(7051):725-30
75. Salmena L, Carracedo A, Pandolfi PP. Tenets of PTEN tumor suppression. Cell 2008;133(3):403-14
76. Ginn-Pease ME, Eng C. Increased nuclear phosphatase and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res 2003;63(2):282-6
77. Liu JL, Sheng X, Hortobagyi ZK, et al. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 2005;25(14):6211-24
78. Shen WH, Balajee AS, Wang J, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007;128(1):157-70
79. Bristow RG, Zhao H, Fraser M. PTEN knockdown, DNA repair, and chemotherapy response in prostate cancer cell lines [abstract 2009]. Genitourinary Cancers Symposium; 26 - 28 February 2009, Orlando, USA
80. Assinder SJ, Dong Q, Kovacevic Z. The TGF-beta, PI3K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer [review]. Biochem J 2009;417(2):411-21
81. Plas DR, Thompson CB. Akt dependent transformation: there is more than tumour growth than just surviving. Oncogene 2005;24:7435-42
82. Kreisberg JI, Malik SN, Prihoda TJ, et al. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004;64(15):5232-6
83. Ayala G, Thompson T, Yang G, et al. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10(19):6572-8
84. Chee KG, Longmate J, Quinn DI, et al. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer 2007;5(7):433-7
85. Wang X, Yue P, Kim YA, et al. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation. Cancer Res 2008;68(18):7409-18
86. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004;22(12):2336-47
87. Ma WW, Jimeno A. Temsirolimus. Drug Today (Barc) 2007;43:659-69
88. O'Donnell A, Faivre S, Burris III HA, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008;26(10):1588-95
89. George DJ, Armstrong AJ, Creel P. A phase II study of RAD001 in men with hormone-refractory metastatic prostate cancer (HRPC) [abstract 181]. Genitourinary Cancers Symposium; 14 - 16 February 2008, San Francisco, USA
90. Ross RW, Manola J, Oh WK, et al. Phase I trial of RAD001 (R) and docetaxel (D) in castration resistant prostate cancer (CRPC) with FDG-PET assessment of RAD001 activity. J Clin Oncol 2008;26:abstract 5069
91. Miayake H, Tolcher A, Gleave ME. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides. J Natl Cancer Inst 2000;92(1):34-41
92. Raffo AJ, Perlman H, Chen MW. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995;55(19):4438-45
93. Sternberg CN, Dumez H, Van Poppel H, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC, multicenter, randomized, phase II study in patients with castration-resistant prostate cancer. Ann Oncol 2009;20(7):1264-9
94. Liu G, Kelly WK, Wilding G, et al. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 2009;15(9):3172-6
95. MacVicar GR, Greco A, Reeves J, et al. An open-label, multicenter, phase I/II study of AT-101 in combination with docetaxel (D) and prednisone (P) in men with castrate-resistant prostate cancer (CRPC). J Clin Oncol 2009;27(15S):abstract 5062
96. Shariat SF, Lotan Y, Saboorian H, et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer 2004;100(4):751-7
97. Tolcher AW, Papadopoulos K, Patnaik A, et al. Phase I/II open-label study of YM155 plus docetaxel and prednisone in men with hormone refractory prostate cancer (HRPC) [abstract 214]. Genitourinary Cancers Symposium; 26 - 28 February 2009, Orlando, USA
98. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6
99. Fox WD, Higgins B, Maiese KM, et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002;8(10):3226-31
100. Ferrer FA, Miller LJ, Lindquist R, et al. Expression of vascular endothelial growth factor receptors in human prostate cancer. Urology 1999;54(3):567-72
101. Duque JL, Loughlin KR, Adam RM, et al. Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer. Urology 1999;54(3):523-7
102. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42
103. Di Lorenzo G, Figg WD, Fossa SD, et al. Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study. Eur Urol 2008;54(5):1089-94
104. Kelly WK, Halabi S, Carducci M.A., et al. A randomized, double-blind, placebo-controlled phase III trial comparing docetaxel, prednisone, and placebo with docetaxel, prednisone, and bevacizumab in men with metastatic castration-resistant prostate cancer (mCRPC): survival results of CALGB 90401. J Clin Oncol 2010;28(7S):abstract LBA4511
105. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors [review]. Expert Opin Biol Ther 2009;9(2):263-71
106. Isambert N, Freyer G, Zanetta S, et al. A phase I dose escalation and pharmacokinetic study of intravenous aflibercept (VEGF trap) plus docetaxel in patients with advanced solid tumors: preliminary results. J Clin Oncol 2008;26:abstract 3599
107. D'Amato RJ. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082-5
108. Figg WD, Dahut W, Duray P, et al. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 2001;7(7):1888-93
109. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004;22(13):2532-9
110. Cetnar JP, Rosen M.A., Vaughn DJ. Phase II study of sorafenib and docetaxel in men with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2009;27:abstract e16055
111. Chi KN, Ellard SL, Hotte SJ, et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008;19(4):746-51
112. Demers LM, Costa L, Lipton A, et al. Biochemical markers and skeletal metastases. Cancer 2000;88(Suppl 12):2919-26
113. Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities [review]. Nat Rev Cancer 2002;2(8):584-93
114. Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002;94(19):1458-68
115. Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93(2):165-76
116. Dougall WC, Chaisson M. The RANK/RANKL/OPG triad in cancer-induced bone diseases [review]. Cancer Metastasis Rev 2006;25(4):541-9
117. Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 2001;107(10):1235-44
118. Zhang J, Dai J, Yao Z, et al. Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res 2003;63(22):7883-90
119. Smith MR, Egerdie B, Hernandez Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361(8):745-55
120. Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3(2):110-16
121. Guise TA, Mohammad KS. Endothelins in bone cancer metastases. Cancer Treat Res 2004;118:197-212
122. Carducci M.A., Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110(9):1959-66
123. Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with non metastatic, hormone-refractory prostate cancer. Cancer 2008;113(9):2478-87
124. James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial. Eur Urol 2009;55(5):1112-23
125. Chang YM, Kung HJ, Evans CP. Non receptor tyrosine kinases in prostate cancer [review]. Neoplasia 2007;9(2):90-100
126. Sanjay A, Houghton A, Neff L. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signalling, cell adhesion, and osteoclast motility. J Cell Biol 2001;152(1):181-95
127. Soriano P, Montgomery C, Geske R, et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991;64(4):693-702
128. Arnott JA, Zhang X, Sanjay A, et al. Molecular requirements for induction of CTGF expression by TGF-beta1 in primary osteoblasts. Bone 2008;42(5):871-85
129. Lee LF, Guan J, Qiu Y, et al. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol Cell Biol 2001;21(24):8385-97
130. Lara PNJ, Longmate J, Evans CP, et al. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drug 2009;20(3):179-84
131. Tabernero J, Cervantes A, Hoekman K, et al. Phase I study of AZD0530, on oral potent inhibitor of Src kinase: first demonstration of inhibition of Src activity in human cancers. J Clin Oncol 2007;25(18S):abstract 3520
132. Snyder DS. New approved dasatinib regimen available for clinical use [review]. Expert Rev Anticancer Ther 2009;9(3):285-92
133. Yu EY, Wilding G, Posadas E, et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2009;15(23):7421-8
134. Yu E, Massard C, Gross M, et al. A phase II study of once-daily dasatinib for patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 2009;27(15S):abstract 5147
135. Araujo J, Armstrong AJ, Braud EL, et al. Dasatinib and docetaxel combination treatment for patients with castration-resistant progressive prostate cancer: a phase I/II study (CA180086). J Clin Oncol 2009;27(15S):abstract 5061
136. Sanda MG, Ayyagari SR, Jaffee EM, et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994;151:622-8
137. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35
138. Bok RA. Treatment of prostate cancer: therapeutic potential of targeted immunotherapy with APC8015. Ther Clin Risk Man 2008;4(1):79-85
139. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19):3089-94
140. Kantoff P, Higano CS, Berger ER, et al. Updated survival results of the IMPACT trial of sipuleucel-T for metastatic castration-resistant prostate cancer (CRPC) [abstract 8]. Genitourinary Cancers Symposium; 5-7 March 2010, San Francisco, USA
141. Simons JW, Sacks N. Granulocyte-macrophage colony-stimulating factor transduced allogenic cancer cellular immunotherapy: the GVAX® vaccine for prostate cancer. Urol Oncol 2006;24:419-24
142. Higano CS, Corman JM, Smith DC, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008;113(5):975-84
143. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor - secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007;13(13):3883-91
144. Higano C, Saad F, Somer B, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC) [abstract LBA150]. Genitourinary Cancers Symposium; 26 - 28 February 2009, Orlando, USA
145. Small E, Demkow T, Gerritsen WR, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC) [abstract 7]. Genitourinary Cancers Symposium; 26 - 28 February 2009, Orlando, USA
146. Kantoff PW, Schuetz T, Blumenstein BA, et al. Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009;27(15S):abstract 5013
147. Tarassoff CP, Arlen PM, Gulley JL. Therapeutic vaccines for prostate cancer. Oncology 2006;11:451-62
148. Di Paola RS, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006;4:1
149. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28(7):1099-105
150. Slovin SF, Beer TM, Higano CS, et al. Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2009;27(15S):abstract 5138
151. Sznol M, Powderly JD, Smith DC, et al. Safety and antitumor activity of biweekly MDX-1106 (anti-PD-1, BMS-936558/ ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 2010;28(7S):abstract 2506
152. Gan L, Chen S, Wang Y, et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009;69(21):8386-94
153. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin Cancer Res 2008;14(22):7167-72
154. Hussain M, Tangen CM, Lara PN, et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005;23:8724-9
155. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone ormitoxantrone and prednisone. Cancer 2007;110:556-63
156. Sartor AO, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC) [abstract 9]. Genitourinary Cancers Symposium; 5-7 March 2010, San Francisco, USA
157. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008;14(19):6302-9
158. Scher HI, Jia X, de Bono JS, et al. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol 2009;10(3):233-9